Trial Profile
BAY 59-7939 (Factor Xa Inhibitor) Phase II Low Dose Study in Patients With Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Thromboembolism; Thrombosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 12 Sep 2009 New trial record